
|Videos|December 27, 2022
Key Points for the Management of Multiple Sclerosis
Stephen Krieger, MD; Daniel Bandari, MD, MS; Bruce Hughes, MD; Mitzi Williams, MD; and Heidi Crayton, MD, provide key takeaways for the treatment of patients with multiple sclerosis.
Advertisement
Advertisement
Stephen Krieger, MD: Well, speaking of key points coming from you, I want to come around and ask you each for a takeaway, a key point, either from ECTRIMS [European Committee for Treatment and Research in Multiple Sclerosis annual meeting] or just something that you were thinking about at this point, fall of 2022, in MS [multiple sclerosis] care. Dr Hughes, do you want to go first and give a closing takeaway point?
Related to this article

The positive opinion for intravenous ocrelizumab was supported by phase 3 OPERETTA 2 findings demonstrating noninferior relapse control and superior suppression of MRI-detected brain lesions compared with fingolimod in pediatric patients with relapsing MS.

An ACT–based group intervention did not significantly improve resilience at 3 months in patients with MS but was associated with improvements in anxiety, well-being, psychological flexibility, and health-related quality of life.

A recent MS cohort study suggests that higher EBV nuclear antigen 1 antibody levels are associated with a lower risk of confirmed disability worsening, particularly among patients carrying both HLA-A02:01 and HLA-DRB115:01.

The FDA clearance allows AbelZeta to study bispecific CAR T-cell therapy C-CAR168 in refractory progressive multiple sclerosis.
Advertisement
Advertisement


